Amneal Pharmaceuticals (AMRX) Misses Q2 EPS by 1c; Offers FY22 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amneal Reports Second Quarter 2022 Financial Results
August 5, 2022 6:00 AM EDT
Q2 2022 Net Revenue of $559 million; GAAP Net Loss of $121 million; Diluted Loss per Share of $(0.80)
Adjusted EBITDA (1) of $135 million; Adjusted Diluted EPS (1) of $0.19
Updates 2022 Adjusted EBITDA guidance
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) announced its results today for the second quarter ended June 30, 2022.
Solid second quarter results reflect topline growth across all three segments and meaningful acceleration in performance from the first quarter. Our core business is strong as we expect acceleration in... More
